Nebivolol SANDOZ 30 tabl & 60 tabl & 90 tabl 5mg Nebivolol Небиволол-Сандоз

Nebivolol SANDOZ Indications

Essential hypertension. Chronic heart failure as adjunct to standard therapies in elderly patients ≥ 70 years.

Contraindications

Hypersensitivity to the active substance or any other drug. Liver failure or liver function limitation. Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring intravenous drug substances with a positive inotropic effect.

Sick sinus syndrome, including sinuauricular block, atrioventricular block II-III (without artificial pacemaker). Bronchospasm and bronchial asthma in history. Untreated pheochromocytoma. Metabolic acidosis. Bradycardia (before treatment heart rate less than 60 beats per minute). Hypotension (systolic blood pressure less than 90 mmHg. In.), Severe peripheral circulation.

Dosage & Administration

Essential hypertension: for adults the dose is 5 mg (1 tablet) daily nebivolol. The drug can be taken with food, preferably at one and the same time. Anti-hypertensive effect is manifested within 1 - 2 weeks of treatment, but sometimes the optimal effect is observed only after 4 weeks. Nebivolol SANDOZ® can be used both alone and in combination with other antihypertensive agents. Until additional antihypertensive effect was observed only in combination with its 12.5 - 25 mg of hydrochlorothiazide.

Patients with renal insufficiency: The recommended initial dose is 2.5 mg per day. If necessary, the daily dose can be increased to 5 mg.

Patients with hepatic impairment: the experience of the drug in such patients is limited, so the use of Nebivolol is contraindicated.

Elderly patients: patients over 65 years the recommended initial dose is 2.5 mg per day. If necessary, the daily dose can be increased to 5 mg. The experience of the drug in patients older than 75 years is limited, because the appointment of the drug in such patients require caution and close monitoring.

Chronic heart failure: treatment of chronic heart failure, start with a slow dose titration to achieve optimal individual maintenance dose. Such patients prescribed the drug if there is chronic heart failure without acute episodes of decompensation within the last 6 weeks.